Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort

Por Monson, Kelsey R., Goldberg, Mandy, Wu, Hui-Chen, Santella, Regina M., Chung, Wendy K., Terry, Mary Beth
Publicado no Breast Cancer Res (2020)

Co-treatment with a C1B5 peptide of protein kinase Cγ and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation

Por Ishiguro, Susumu, Kawabata, Atsushi, Zulbaran-Rojas, Alejandro, Monson, Kelsey, Uppalapati, Deepthi, Ohta, Naomi, Inui, Makoto, Pappas, Charalampos G., Tzakos, Andreas G., Tamura, Masaaki
Publicado no Biochem Biophys Res Commun (2017)

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

Por Hyman, David M., Snyder, Alexandra E., Carvajal, Richard D., Gerecitano, John F., Voss, Martin H., Ho, Alan L., Konner, Jason, Winkelmann, Jennifer L., Stasi, Megan A., Monson, Kelsey R., Iasonos, Alexia, Spriggs, David R., Bialer, Philip, Lacouture, Mario E., Teitcher, Jerrold B., Katabi, Nora, Fury, Matthew G.
Publicado no Cancer Chemother Pharmacol (2015)

A phase 1b dose expansion study of the pan-Class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin...

Por Smyth, Lillian M., Monson, Kelsey R., Jhaveri, Komal, Drilon, Alexander, Li, Bob T, Abida, Wassim, Iyer, Gopa, Gerecitano, John F., Gounder, Mrinal, Harding, James J., Voss, Martin H., Makker, Vicky, Ho, Alan L., Razavi, Pedram, Iasonos, Alexia, Bialer, Philip, Lacouture, Mario E., Teitcher, Jerrold B., Erinjeri, Joseph P., Katabi, Nora, Fury, Matthew G., Hyman, David M.
Publicado no Invest New Drugs (2017)